Saluda Medical Announces Robust Scientific Presence at 2022 International Neuromodulation Society (INS) World Congress

18 posters and 9 oral presentations highlight Saluda’s continued leadership in paradigm-shifting closed-loop technology with real-time ECAP sensing and controlled neural activation.

Artarmon, Australia -- Key data highlights with the Evoke^® System to include holistic composite treatment outcomes for disrupting the chronic pain cycle; opioid-sparing effects of therapy; real-world results; and cost-effectiveness compared to open-loop stimulation.

Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced neural activation and sensing technologies designed to treat debilitating neurological disorders, announced the scientific presentation schedule at the 2022 International Neuromodulation Society (INS) 15^th World Congress to be held May 21-26, 2022, in Barcelona, Spain. The schedule includes a record-breaking scientific presence for Saluda with eighteen posters, nine of which were awarded oral presentations and three of which include late breaking data.

Saluda Medical’s Evoke^® System is the first and only available closed-loop spinal cord stimulation system to maintain consistent therapy through dynamic sensing technology that automatically senses and responds to the level of neural activation – more than 100+ times per second – to deliver long-term superior outcomes. Results shared at INS will highlight outcomes from the AVALON and EVOKE Studies, including holistic composite improvements in pain relief, quality of life, function, and sleep; cost-effectiveness of the Evoke System in comparison to open-loop and high frequency stimulation; and opioid-sparing effects of treatment. Other important data to be presented includes 12-month real-world results from Europe and important findings around the impact of accurate neural activation on long-term outcomes at 24 months.

“INS is one of the premier international neuromodulation meetings and we are pleased to see the significant scientific presence highlighting the paradigm shift in spinal cord stimulation technology,” said Jim Schuermann, President and CEO of Saluda Medical. “This meeting represents the most posters and podium presentations in our company’s history demonstrating the growing level of scientific interest in the Evoke Closed-Loop evidence and elevation of SCS standard of care.”

• Most popular related searches

  • spinal cord stimulation
  • spinal cord
  • medical device
  • neurology disorder
  • chronic pain
  • spinal
  • spinal system
  • neurology
  • medical research
  • medical data